To All:
It seems that GenSci (Biocoll) is starting to attract more institutional interest (about time!). The following news release, previous news, corporate info, links, etc. are available at fin-info.com
Garth.
ETOBICOKE, Ont., Aug. 13 /CNW/ - Canadian Medical Discoveries Fund Inc.
(``CMDF'') today announced that it has completed the acquisition of 3,274,007
Common shares of GenSci Regeneration Sciences Inc. (GenSci). GenSci, formerly
Biocoll Medical Corp., was created as a result of the amalgamation of Biocoll
Medical Corp. and Osteopharm Limited.
Subsequent to this amalgamation, CMDF has an approximate 16.8% interest
in the capital of GenSci.
GenSci is a publicly traded company, listed on the Vancouver Stock
Exchange, dedicated to the development of innovative bone and tissue
regeneration technologies through its bioimplant division and is aggressively
moving toward the development of a new family of compounds for the treatment
and diagnosis of osteoporosis through its pharmaceutical division.
CMDF is a labour sponsored venture capital fund focused on achieving
superior long-term capital appreciation by investing in life science
businesses engaged in early-stage commercialization of research and/or product
development. CMDF is managed by Medical Discoveries Management Corporation
and by MDS Capital Corp. MDS targets over C$500 million in investment capital
towards building companies in the health care and biotechnology industries.
CMDF has acquired the Common shares for investment purposes. |
